NCT02484404: Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

NCT02484404
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Tyrosine-Kinase Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Only TNBC patients with germline BRCA1/2 mutation will be eligible for Phase II of the study
Exclusions: 
https://ClinicalTrials.gov/show/NCT02484404

Comments are closed.

Up ↑